Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Lung Cancer-Associated Brain Metastasis: Molecular Mechanisms and Therapeutic Options Publisher Pubmed



Yousefi M1, 2 ; Bahrami T3 ; Salmaninejad A4 ; Nosrati R5 ; Ghaffari P2 ; Ghaffari SH2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Genetics, Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Genetic Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
  4. 4. Drug Applied Research Center, Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
  5. 5. Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Cellular Oncology Published:2017


Abstract

Background: Lung cancer is the most common cause of cancer-related mortality in humans. There are several reasons for this high rate of mortality, including metastasis to several organs, especially the brain. In fact, lung cancer is responsible for approximately 50% of all brain metastases, which are very difficult to manage. Understanding the cellular and molecular mechanisms underlying lung cancer-associated brain metastasis brings up novel therapeutic promises with the hope to ameliorate the severity of the disease. Here, we provide an overview of the molecular mechanisms underlying the pathogenesis of lung cancer dissemination and metastasis to the brain, as well as promising horizons for impeding lung cancer brain metastasis, including the role of cancer stem cells, the blood-brain barrier, interactions of lung cancer cells with the brain microenvironment and lung cancer-driven systemic processes, as well as the role of growth factor/receptor tyrosine kinases, cell adhesion molecules and non-coding RNAs. In addition, we provide an overview of current and novel therapeutic approaches, including radiotherapy, surgery and stereotactic radiosurgery, chemotherapy, as also targeted cancer stem cell and epithelial-mesenchymal transition (EMT)-based therapies, micro-RNA-based therapies and other small molecule or antibody-based therapies. We will also discuss the daunting potential of some combined therapies. Conclusions: The identification of molecular mechanisms underlying lung cancer metastasis has opened up new avenues towards their eradication and provides interesting opportunities for future research aimed at the development of novel targeted therapies. © 2017, International Society for Cellular Oncology.
Other Related Docs
17. Overview of Liquid Biopsy, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)
18. Spatial Profiling Technologies and Applications for Brain Cancers, Expert Review of Molecular Diagnostics (2021)
26. Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond, Archivum Immunologiae et Therapiae Experimentalis (2019)
30. Tumor Immunology, Clinical Immunology (2022)
33. Liquid Biopsy in Thyroid Cancer: New Insight, International Journal of Hematology-Oncology and Stem Cell Research (2018)
36. Critical Roles of Mir-21 in Promotions Angiogenesis: Friend or Foe?, Clinical and Experimental Medicine (2025)
41. Atm in Breast and Brain Tumors: A Comprehensive Review, Cancer Biology and Medicine (2018)
43. Melatonin for Gastric Cancer Treatment: Where Do We Stand?, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)